Modeling the economic burden of adult vaccine-preventable diseases in the United States

Sachiko Ozawa, Allison Portnoy, Hiwote Getaneh, Samantha Clark, Maria Knoll, David Bishai, H. Keri Yang, Pallavi D. Patwardhan

Research output: Contribution to journalArticlepeer-review

Abstract

Vaccines save thousands of lives in the United States every year, but many adults remain unvaccinated. Low rates of vaccine uptake lead to costs to individuals and society in terms of deaths and disabilities, which are avoidable, and they create economic losses from doctor visits, hospitalizations, and lost income. To identify the magnitude of this problem, we calculated the current economic burden that is attributable to vaccine-preventable diseases among US adults. We estimated the total remaining economic burden at approximately $9 billion (plausibility range: $4.7-$15.2 billion) in a single year, 2015, from vaccine-preventable diseases related to ten vaccines recommended for adults ages nineteen and older. Unvaccinated individuals are responsible for almost 80 percent, or $7.1 billion, of the financial burden. These results not only indicate the potential economic benefit of increasing adult immunization uptake but also highlight the value of vaccines. Policies should focus on minimizing the negative externalities or spillover effects from the choice not to be vaccinated, while preserving patient autonomy.

Original languageEnglish (US)
Pages (from-to)2124-2132
Number of pages9
JournalHealth Affairs
Volume35
Issue number11
DOIs
StatePublished - 2016

ASJC Scopus subject areas

  • Health Policy

Fingerprint Dive into the research topics of 'Modeling the economic burden of adult vaccine-preventable diseases in the United States'. Together they form a unique fingerprint.

Cite this